Division of Nephrology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Am J Transplant. 2022 Jan;22(1):245-259. doi: 10.1111/ajt.16865. Epub 2021 Nov 1.
While older males are at the highest risk for poor coronavirus disease 2019 (COVID-19) outcomes, it is not known if this applies to the immunosuppressed recipient of a solid organ transplant (SOT), nor how the type of allograft transplanted may impact outcomes. In a cohort study of adult (>18 years) patients testing positive for COVID-19 (January 1, 2020-June 21, 2021) from 56 sites across the United States identified using the National COVID Cohort Collaborative (N3C) Enclave, we used multivariable Cox proportional hazards models to assess time to MARCE after COVID-19 diagnosis in those with and without SOT. We examined the exposure of age-stratified recipient sex overall and separately in kidney, liver, lung, and heart transplant recipients. 3996 (36.4%) SOT and 91 646 (4.8%) non-SOT patients developed MARCE. Risk of post-COVID outcomes differed by transplant allograft type with heart and kidney recipients at highest risk. Males with SOT were at increased risk of MARCE, but to a lesser degree than the non-SOT cohort (HR 0.89, 95% CI 0.81-0.98 for SOT and HR 0.61, 95% CI 0.60-0.62 for non-SOT [females vs. males]). This represents the largest COVID-19 SOT cohort to date and the first-time sex-age-stratified and allograft-specific COVID-19 outcomes have been explored in those with SOT.
虽然老年男性患 2019 年冠状病毒病(COVID-19)的风险最高,但尚不清楚这是否适用于实体器官移植(SOT)受者的免疫抑制患者,也不清楚移植的同种异体类型如何影响结果。在美国 56 个地点使用国家 COVID 队列协作(N3C)飞地从 2020 年 1 月 1 日至 2021 年 6 月 21 日对 COVID-19 检测呈阳性的成年(>18 岁)患者进行的一项队列研究中,我们使用多变量 Cox 比例风险模型来评估 COVID-19 诊断后发生 MARCE 的时间在有和没有 SOT 的患者中。我们检查了受体性别分层的暴露情况,总体上和分别在肾、肝、肺和心脏移植受者中进行了检查。3996 例(36.4%)SOT 和 91646 例(4.8%)非 SOT 患者发生了 MARCE。移植同种异体类型的 COVID 后结果风险不同,心脏和肾脏受者的风险最高。SOT 男性发生 MARCE 的风险增加,但程度低于非 SOT 队列(SOT 的 HR 0.89,95%CI 0.81-0.98,非 SOT 的 HR 0.61,95%CI 0.60-0.62 [女性与男性])。这是迄今为止最大的 COVID-19 SOT 队列,也是首次对 SOT 患者进行按性别-年龄分层和同种异体特异性 COVID-19 结果的探索。